Imaging Can Predict Early Response to Cancer Treatment

-- A. Agrawal, PhD

Wednesday, November 18, 2009

WEDNESDAY, Nov. 18 (HealthDay News) -- Imaging by combined positron emission tomography and computed tomography (PET-CT) can accurately assess early treatment response to chemoradiotherapy of head and neck cancer, according to a study in the November issue of Archives of Otolaryngology -- Head & Neck Surgery.

James P. Malone, M.D., from the Southern Illinois School of Medicine in Springfield, and colleagues retrospectively analyzed data from combined PET-CT in 31 patients with advanced squamous cell carcinoma of the head and neck, taken six to eight weeks after chemoradiotherapy.

After a median follow-up of 24 months, the researchers found that assessment of tumor response by PET-CT at the primary site had a sensitivity of 83 percent, a specificity of 54 percent, a positive predictive value of 31 percent, and a negative predictive value of 92 percent. In patients who had node-positive disease before treatment, use of PET-CT had a specificity of more than 94 percent and a negative predictive value of 94 percent. In patients who were node negative before treatment, use of PET-CT had a specificity of 92 percent and a negative predictive value of more than 92 percent.

"Negative PET-CT findings accurately determine early disease response at the primary site and in the neck," Malone and colleagues conclude. "Patients with a negative PET-CT finding after the completion of intra-arterial chemoradiotherapy do not require surgical intervention."

Abstract
Full Text (subscription or payment may be required)

Specialties Cardiology
Diabetes & Endocrinology
Internal Medicine
Family Practice

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Blogs

Continuing Education for Social Workers and Nurses
by OncoLink Editorial Team
September 30, 2014

Don't Assume You Understand
by Bob Riter
July 29, 2015